NYNa Yang

Na Yang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Na Yang has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Beibei Zhang

    Institute of Biomedical Research Yunnan University Kunming Yunnan China

    1 shared publication
  • Daogang Wang

    Department of Gastroenterology, The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, China

    1 shared publication
  • Liangfang Jing

    Department of Neonatology, Women and Children’s Hospital of Guangxi Zhuang Autonomous Region, Nanning, China

    1 shared publication
  • Mengzhe Yang

    Graduate School of Capital Medical University, Beijing, China

    1 shared publication
  • Ning Liu

    Department of Hematology, Huazhong University of Science and Technology Union Shenzhen Hospital, Shenzhen, China

    1 shared publication
  • Ning Xu

    Department of Clinical Medicine, The Fifth Affiliated Hospital of Guangxi Medical University, Nanning, China

    1 shared publication

Latest Publications

  • Open Access

    Chimeric antigen receptor-based natural killer cell immunotherapy in cancer: from bench to bedside

    by Beibei Zhang, Mengzhe Yang, Weiming Zhang, Ning Liu, Daogang Wang, Liangfang Jing, Ning Xu, Na Yang, Tao Ren

    Immunotherapy has rapidly evolved in the past decades in the battle against cancer. Chimeric antigen receptor (CAR)-engineered T cells have demonstrated significant success in certain hematologic malignancies, although they still face certain limitations, including high costs and toxic effects. Natural killer cells (NK cells), as a vital component of the immune system, serve as the “first responders” in the context of cancer development. In this literature review, we provide an updated understanding of NK cell development, functions, and their applications in disease therapy. Furthermore, we explore the rationale for utilizing engineered NK cell therapies, such as CAR-NK cells, and discuss the differences between CAR-T and CAR-NK cells. We also provide insights into the key elements and strategies involved in CAR design for engineered NK cells. In addition, we highlight the challenges currently encountered and discuss the future directions in NK cell research and utilization, including pre-clinical investigations and ongoing clinical trials. Based on the outstanding antitumor potential of NK cells, it is highly likely that they will lead to groundbreaking advancements in cancer treatment in the future.